These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8896905)

  • 1. Impact of concentrations of glycated hemoglobin, alpha-tocopherol, copper, and manganese on oxidation of low-density lipoproteins in patients with type I diabetes, type II diabetes and control subjects.
    Leonhardt W; Hanefeld M; Müller G; Hora C; Meissner D; Lattke P; Paetzold A; Jaross W; Schroeder HE
    Clin Chim Acta; 1996 Oct; 254(2):173-86. PubMed ID: 8896905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.
    Fuller CJ; Chandalia M; Garg A; Grundy SM; Jialal I
    Am J Clin Nutr; 1996 May; 63(5):753-9. PubMed ID: 8615360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced susceptibility of low-density lipoprotein to in vitro oxidation in type 1 and type 2 diabetic patients.
    Beaudeux JL; Guillausseau PJ; Peynet J; Flourie F; Assayag M; Tielmans D; Warnet A; Rousselet F
    Clin Chim Acta; 1995 Aug; 239(2):131-41. PubMed ID: 8542651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is glycation of low density lipoproteins in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition?
    Moro E; Alessandrini P; Zambon C; Pianetti S; Pais M; Cazzolato G; Bon GB
    Diabet Med; 1999 Aug; 16(8):663-9. PubMed ID: 10477211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of low- and high-density lipoproteins from diabetic subjects to in vitro oxidative modification.
    Julier K; Mackness MI; Dean JD; Durrington PN
    Diabet Med; 1999 May; 16(5):415-23. PubMed ID: 10342342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Vitamin E on susceptibility of low-density lipoprotein and low-density lipoprotein subfractions to oxidation and on protein glycation in NIDDM.
    Reaven PD; Herold DA; Barnett J; Edelman S
    Diabetes Care; 1995 Jun; 18(6):807-16. PubMed ID: 7555507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transport of vitamin E in plasma and its correlation to plasma lipoproteins in non-insulin-dependent diabetes mellitus.
    Kökoğlu E; Ulakoğlu E
    Diabetes Res Clin Pract; 1991 Dec; 14(3):175-81. PubMed ID: 1778110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of low density lipoprotein (LDL) subfraction profile and LDL oxidation on endothelium-dependent and independent vasodilation in patients with type 2 diabetes.
    Tan KC; Ai VH; Chow WS; Chau MT; Leong L; Lam KS
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3212-6. PubMed ID: 10487689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased DNA oxidative susceptibility without increased plasma LDL oxidizability in Type II diabetes: effects of alpha-tocopherol supplementation.
    Sampson MJ; Astley S; Richardson T; Willis G; Davies IR; Hughes DA; Southon S
    Clin Sci (Lond); 2001 Sep; 101(3):235-41. PubMed ID: 11524040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin E supplementation and oxidative damage to DNA and plasma LDL in type 1 diabetes.
    Astley S; Langrish-Smith A; Southon S; Sampson M
    Diabetes Care; 1999 Oct; 22(10):1626-31. PubMed ID: 10526726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification.
    Sánchez-Quesada JL; Pérez A; Caixàs A; Rigla M; Payés A; Benítez S; Ordóñez-Llanos J
    J Clin Endocrinol Metab; 2001 Jul; 86(7):3243-9. PubMed ID: 11443196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
    Sanguinetti SM; Brites FD; Fasulo V; Verona J; Elbert A; Wikinski RL; Schreier LE
    Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole plasma oxidation assay as a measure of lipoprotein oxidizability.
    Kontush A; Spranger T; Reich A; Djahansouzi S; Karten B; Braesen JH; Finckh B; Kohlschütter A; Beisiegel U
    Biofactors; 1997; 6(2):99-109. PubMed ID: 9259991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients.
    Oranje WA; Sels JP; Rondas-Colbers GJ; Lemmens PJ; Wolffenbuttel BH
    Clin Chim Acta; 2001 Sep; 311(2):91-4. PubMed ID: 11566168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus.
    Anderson JW; Gowri MS; Turner J; Nichols L; Diwadkar VA; Chow CK; Oeltgen PR
    J Am Coll Nutr; 1999 Oct; 18(5):451-61. PubMed ID: 10511327
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of fluvastatin therapy on lipids, antioxidants, oxidation of low density lipoproteins and trace metals.
    Leonhardt W; Kurktschiev T; Meissner D; Lattke P; Abletshauser C; Weidinger G; Jaross W; Hanefeld M
    Eur J Clin Pharmacol; 1997; 53(1):65-9. PubMed ID: 9349932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Susceptibility of LDL to oxidation is not associated with the presence of coronary heart disease or renal dysfunction in NIDDM patients.
    Leinonen JS; Rantalaiho V; Solakivi T; Koivula T; Wirta O; Pasternack A; Alho H; Lehtimäki T
    Clin Chim Acta; 1998 Jul; 275(2):163-74. PubMed ID: 9721074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations of LDL size with in vitro oxidizability and plasma levels of in vivo oxidized LDL in Type 2 diabetic patients.
    Scheffer PG; Bos G; Volwater HG; Dekker JM; Heine RJ; Teerlink T
    Diabet Med; 2003 Jul; 20(7):563-7. PubMed ID: 12823238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, single-blind, placebo-controlled trial of the effects of 200 mg alpha-tocopherol on the oxidation resistance of atherogenic lipoproteins.
    Porkkala-Sarataho EK; Nyyssönen MK; Kaikkonen JE; Poulsen HE; Hayn EM; Salonen RM; Salonen JT
    Am J Clin Nutr; 1998 Nov; 68(5):1034-41. PubMed ID: 9808219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predisposition to LDL oxidation during copper-catalyzed oxidative modification and its relation to alpha-tocopherol content in humans.
    Cominacini L; Garbin U; Cenci B; Davoli A; Pasini C; Ratti E; Gaviraghi G; Lo Cascio V; Pastorino AM
    Clin Chim Acta; 1991 Dec; 204(1-3):57-68. PubMed ID: 1819474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.